MEI Pharma, Inc. Contracts & Agreements

Separation and Release Agreement, dated as of August 3, 2024, by and between MEI Pharma, Inc. and Richard G. Ghalie (Filed With SEC on November 12, 2024)

Separation and Release Agreement, dated as of August 4, 2024, by and between MEI Pharma, Inc. and David M. Urso (Filed With SEC on November 12, 2024)

Consulting Services Agreement, dated as of August 2, 2024, by and between MEI Pharma, Inc. and Richard G. Ghalie (Filed With SEC on November 12, 2024)

Consulting Services Agreement, dated as of August 2, 2024, by and between MEI Pharma, Inc. and David M. Urso (Filed With SEC on November 12, 2024)

Asset Purchase Agreement, by and between MEI Pharma, Inc. and Aardvark Therapeutics, Inc., dated as of October 22, 2024 (Filed With SEC on October 25, 2024)

Addendum to Employment Agreement between MEI Pharma, Inc. and Justin J. File, dated August 1, 2024 (Filed With SEC on September 19, 2024)

Amended and Restated 2008 Stock Omnibus Equity Compensation Plan (December 2023) (Filed With SEC on May 9, 2024)

Sales Agreement by and between MEI Pharma, Inc. and JonesTrading Institutional Services LLC, dated as of February 20, 2024 (Filed With SEC on February 21, 2024)

Employment Agreement between MEI Pharma, Inc. and Richard Ghalie dated January 16, 2024 (Filed With SEC on February 13, 2024)

Cooperation Agreement, dated as of October 31, 2023, by and among the Investors and the Company (Filed With SEC on November 1, 2023)

Rights Agreement, dated as of October 1, 2023, by and between MEI Pharma, Inc. and Computershare, Inc., as rights agent (Filed With SEC on October 3, 2023)

Description of MEI Common Stock (Filed With SEC on September 26, 2023)

Form of Warrant (Filed With SEC on September 26, 2023)

Separation and Release Agreement between the Company and Brian Drazba, dated June 16, 2023 (Filed With SEC on July 27, 2023)

Termination Letter from MEI Pharma, Inc. to Infinity Pharmaceuticals, Inc., dated July 23, 2023 (Filed With SEC on July 24, 2023)

Termination Agreement, by and between MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. (formerly known as Kyowa Hakko Kirin Co., Ltd.) dated as of July 14, 2023 (Filed With SEC on July 19, 2023)

Employee Proprietary Information and Inventions Agreement between the Company and Jay File, dated June 9, 2023 (Filed With SEC on June 13, 2023)

Employment Agreement between the Company and Jay File, dated June 9, 2023 (Filed With SEC on June 13, 2023)

Amended and Restated MEI Pharma, Inc. 2021 Inducement Grant Equity Compensation Plan (Filed With SEC on June 13, 2023)

CEO Employment Agreement between the Company and David Urso, dated June 2, 2023 (Filed With SEC on June 2, 2023)

Agreement and Plan of Merger, by and among the Company, Merger Sub, and Infinity, dated as of February 22, 2023 (Filed With SEC on February 23, 2023)

Letter Agreement between Brian G. Drazba and MEI Pharma, Inc., dated as of July 7, 2022 (Filed With SEC on July 7, 2022)

Letter Agreement between Brian G. Drazba and MEI Pharma, Inc. dated as of December 21, 2021 (Filed With SEC on December 23, 2021)

Underwriting Agreement, dated as of December 1, 2021, by and among the Company, Jefferies LLC, Stifel, Nicolaus & Company, Incorporated, and Wells Fargo Securities, LLC, as... (Filed With SEC on December 6, 2021)

Employment letter dated February 17, 2016, between MEI Pharma, Inc. and Richard G. Ghalie (Filed With SEC on September 2, 2021)

Amendment 2021-1 dated April 29, 2021, to the Employment letter dated February 17, 2016, between MEI Pharma, Inc. and Richard G. Ghalie (Filed With SEC on September 2, 2021)

Transition and Retirement Agreement between Brian G. Drazba and MEI Pharma, Inc., dated as of August 2, 2021 (Filed With SEC on August 5, 2021)

Amended and Restated 2008 Stock Omnibus Equity Compensation Plan (Filed With SEC on December 17, 2020)

Sales Agreement dated November 10, 2020 (Filed With SEC on November 10, 2020)

Description of Capital Stock of MEI Pharma, Inc (Filed With SEC on September 9, 2020)

License, Development and Commercialization Agreement, dated as of April 13, 2020, by and between the Company and Kyowa Kirin Co., Ltd. (formerly known as Kyowa Hakko Kirin Co.,... (Filed With SEC on September 9, 2020)

Underwriting Agreement, dated as of December 17, 2019, between the Company, Stifel, Nicolaus & Company, Incorporated and Wells Fargo Securities, LLC, as representatives of the... (Filed With SEC on December 18, 2019)

License, Development and Commercialization Agreement, dated as of October 31, 2018, by and between the Company and Kyowa Hakko Kirin Co., Ltd (Filed With SEC on February 7, 2019)

Amended and Restated 2008 Stock Omnibus Equity Compensation Plan (Filed With SEC on November 30, 2018)

Amendment No. 1, dated July 12, 2018, to the Employment Letter dated March 6, 2014, between MEI Pharma, Inc. and David M. Urso (Filed With SEC on July 16, 2018)

Form of Warrant (incorporated by reference to Exhibit 10.1) (Filed With SEC on May 16, 2018)

Registration Rights Agreement dated May 16, 2018, between MEI Pharma, Inc. and the purchasers identified in Exhibit A therein (Filed With SEC on May 16, 2018)

License Agreement, dated as of September 5, 2017, by and between MEI Pharma, Inc. and Presage Biosciences, Inc (Filed With SEC on November 8, 2017)

Sales Agreement dated November 8, 2017 (Filed With SEC on November 8, 2017)

11975 El Camino Real, #101 San Diego, CA 92130 ###-###-#### (Filed With SEC on April 3, 2017)

MEI PHARMA, INC. AMENDED AND RESTATED 2008 STOCK OMNIBUS EQUITY COMPENSATION PLAN (Filed With SEC on December 2, 2016)

MEI PHARMA, INC. AMENDED AND RESTATED 2008 STOCK OMNIBUS EQUITY COMPENSATION PLAN (Filed With SEC on December 4, 2015)

MEI PHARMA, INC. (a Delawarecorporation) 10,000,000 Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on December 17, 2014)

MEI PHARMA, INC. AMENDED AND RESTATED 2008 STOCK OMNIBUS EQUITY COMPENSATION PLAN (Filed With SEC on December 4, 2014)

11975 El Camino Real, #101 San Diego, CA 92130 ###-###-#### (Filed With SEC on April 8, 2014)

4,375,000 Shares MEI PHARMA,INC. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on October 29, 2013)

2,030,000 Shares MEI PHARMA, INC. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on April 10, 2013)

MEI PHARMA, INC. AMENDED AND RESTATED 2008 STOCK OMNIBUS EQUITY COMPENSATION PLAN (Filed With SEC on March 29, 2013)

AGREEMENT (Filed With SEC on December 7, 2012)

LICENSE AGREEMENT BETWEEN CYDEX PHARMACEUTICALS, INC. AND MEI PHARMA, INC. DATED: September 28, 2012 TABLE OF CONTENTS (Filed With SEC on November 13, 2012)

SUPPLY AGREEMENT BETWEEN CYDEX PHARMACEUTICALS, INC. AND MEI PHARMA, INC. DATED: September 28, 2012 TABLE OF CONTENTS (Filed With SEC on November 13, 2012)

WARRANT (Filed With SEC on November 5, 2012)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on November 5, 2012)

GOVERNANCE AGREEMENT (Filed With SEC on November 5, 2012)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on November 5, 2012)

ASSET PURCHASE AGREEMENT by and between MEI Pharma, Inc. as Purchaser, and S*BIO Pte Ltd. as Seller Dated as of August 7, 2012 Table of Contents (Filed With SEC on August 8, 2012)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on August 8, 2012)

FORM OF SUBSCRIPTION AGENT AGREEMENT (Filed With SEC on March 20, 2012)

[Letterhead of Georgeson Inc.] (Filed With SEC on March 20, 2012)

MARSHALL EDWARDS, INC. FORM OF SUBSCRIPTION RIGHTS CERTIFICATE (Filed With SEC on March 20, 2012)

FORM OF WARRANT AGREEMENT (Filed With SEC on March 20, 2012)

SECURITIES SUBSCRIPTION AGREEMENT (Filed With SEC on December 29, 2011)

MARSHALL EDWARDS, INC. AMENDED AND RESTATED 2008 STOCK OMNIBUS EQUITY COMPENSATION PLAN (Filed With SEC on December 5, 2011)

FORM OF AMENDED AND RESTATED SERIES A WARRANT (Filed With SEC on September 29, 2011)

FORM OF AMENDED AND RESTATED SERIES B WARRANT (Filed With SEC on September 29, 2011)

SECURITIES SUBSCRIPTION AGREEMENT (Filed With SEC on September 29, 2011)

140 Wicks Road, North Ryde NSW 2113 Tel: +6 12 9878 0088 Fax: +61 2 9878 0055 (Filed With SEC on September 29, 2011)

FORM OF SUPPLEMENTAL AGREEMENT (Filed With SEC on September 29, 2011)

INDEMNIFICATION AGREEMENT (Filed With SEC on August 29, 2011)

MARSHALL EDWARDS, INC. (Filed With SEC on June 2, 2011)

MARSHALL EDWARDS, INC. NONQUALIFIED STOCK OPTION GRANT (Filed With SEC on June 2, 2011)

AMENDED AND RESTATED SECURITIES PURCHASE AGREEMENT (Filed With SEC on May 16, 2011)

AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (Filed With SEC on May 16, 2011)

AMENDED AND RESTATED VOTING AGREEMENT (Filed With SEC on May 16, 2011)

MARSHALL EDWARDS, INC. Form of Amended and Restated Lock-Up Agreement May 16, 2011 (Filed With SEC on May 16, 2011)

FORM OF SERIES A WARRANT (Filed With SEC on May 16, 2011)

FORM OF SERIES B WARRANT (Filed With SEC on May 16, 2011)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on May 2, 2011)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on May 2, 2011)

VOTING AGREEMENT (Filed With SEC on May 2, 2011)

MARSHALL EDWARDS, INC. Form of Lock-Up Agreement May 2, 2011 (Filed With SEC on May 2, 2011)

[FORM OF SERIES [A][B][C] WARRANT] (Filed With SEC on May 2, 2011)

STOCK PURCHASE AGREEMENT (Filed With SEC on March 18, 2011)

MARSHALL EDWARDS, INC. Common Stock (par value $0.00000002 per share) At Market Issuance Sales Agreement (Filed With SEC on February 7, 2011)

ASSETPURCHASE AGREEMENT BETWEEN MARSHALL EDWARDS, INC., AS BUYER, NOVOGEN LIMITED, AS SELLER PARENT, AND NOVOGEN RESEARCH PTY LIMITED, AS SELLER DATED AS OF DECEMBER 21, 2010... (Filed With SEC on December 22, 2010)

MARSHALL EDWARDS, INC. (Filed With SEC on June 23, 2010)

EXHIBIT A (Filed With SEC on June 23, 2010)

MARSHALL EDWARDS, INC. (Filed With SEC on April 26, 2010)

EX-4.1: WARRANT (Filed With SEC on July 30, 2008)

EX-10.1: SECURITIES SUBSCRIPTION AGREEMENT (Filed With SEC on July 30, 2008)

CUSIP Holder ID Insurance Value Number of Shares DTC XXXXXX XX X XXXXXXXXXX 1,000,000.00 123456 12345678 123456789012345 Certificate Numbers Num/No. Denom. Total1234567890... (Filed With SEC on September 27, 2007)

AMENDED AND RESTATED (Filed With SEC on September 27, 2007)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on September 27, 2007)

August 6, 2007 NOS. (Filed With SEC on September 27, 2007)

EX-10.1: SECURITIES SUBSCRIPTION AGREEMENT (Filed With SEC on August 6, 2007)

EX-10.2: REGISTRATION RIGHTS AGREEMENT (Filed With SEC on August 6, 2007)

EX-10.3: WARRANT AGREEMENT (Filed With SEC on August 6, 2007)

EX-10.4: FORM OF WARRANT (Filed With SEC on August 6, 2007)

EX-10.1: AMENDMENT DEED (Filed With SEC on April 5, 2007)

EX-10.1: SECURITIES SUBSCRIPTION AGREEMENT (Filed With SEC on July 12, 2006)

SECURITIES SUBSCRIPTION AGREEMENT (Filed With SEC on July 12, 2006)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on July 12, 2006)

WARRANT AGREEMENT (Filed With SEC on July 12, 2006)

EX-10.1: STANDBY EQUITY DISTRIBUTION AGREEMENT (Filed With SEC on July 12, 2006)

FORM OF WARRANT (Filed With SEC on July 12, 2006)

EX-10.2: REGISTRATION RIGHTS AGREEMENT (Filed With SEC on July 12, 2006)

EX-10.1: AMENDMENT DEED (Filed With SEC on June 9, 2006)

SPECIMEN COMMON STOCK CERTIFICATE (Filed With SEC on October 31, 2003)

WARRANT AGREEMENT (Filed With SEC on October 31, 2003)

OPINION OF MORGAN, LEWIS & BOCKIUS LLP (Filed With SEC on October 31, 2003)

AMENDED AND RESTATED LICENSE AGREEMENT (Filed With SEC on September 25, 2003)

AMEND. & RESTATED MANUFACTURING LICENSE/SUPPLY AGR (Filed With SEC on September 25, 2003)

AMENDED AND RESTATED LICENSE OPTION DEED (Filed With SEC on September 25, 2003)

AMENDED AND RESTATED SERICES AGREEMENT (Filed With SEC on September 25, 2003)

GUARANTEE AND INDEMNITY (Filed With SEC on September 25, 2003)

MARSHALL EDWARDS INC. SHARE OPTION PLAN (Filed With SEC on September 25, 2003)

FORM OF OUTSTANDING WARRANT (Filed With SEC on September 25, 2003)

Category

Industry

Companies

Contracts

MEI Pharma, Inc. Contracts & Agreements